Skip to main content
Erschienen in: Reactions Weekly 1/2022

01.10.2022 | Case report

Ixekizumab

Recurrent oral candidiasis: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Megna M, et al. Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: Results from an Italian single-center retrospective study in a real-life setting. Dermatologic Therapy 35: e15667, No. 9, Sep 2022. Available from: URL: http://doi.org/10.1111/dth.15667 Megna M, et al. Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: Results from an Italian single-center retrospective study in a real-life setting. Dermatologic Therapy 35: e15667, No. 9, Sep 2022. Available from: URL: http://​doi.​org/​10.​1111/​dth.​15667
Metadaten
Titel
Ixekizumab
Recurrent oral candidiasis: case report
Publikationsdatum
01.10.2022
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2022
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-022-25045-3

Weitere Artikel der Ausgabe 1/2022

Reactions Weekly 1/2022 Zur Ausgabe

Case report

Dupilumab

Case report

Multiple drugs

Case report

Tozinameran